Day One Biopharmaceuticals announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the investigational agent tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma, pLGG, in Nature Medicine. Subsets of the data will also be presented today in two oral plenary presentations at the 2023 Society for Neuro-Oncology, SNO, Annual Meeting in Vancouver, Canada. “The study results published in Nature Medicine demonstrate promising evidence with respect to the the impact of tovorafenib for children and young adults with BRAF-altered relapsed or progressive pLGG, a debilitating form of brain tumor that currently has no approved systemic therapies,” said Dr. Samuel Blackman, co-founder and head of research and development, Day One. “We look forward to continued development of tovorafenib.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
- Day One Biopharmaceuticals reports Q3 EPS (54c), consensus (60c)
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
- DAWN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Xoma earns $5M milestone upon FDA acceptance of Day One’s tovorafenib NDA